Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis

[1]  A. Logan,et al.  Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia , 2022, American journal of hematology.

[2]  B. Cho,et al.  A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML) , 2022, Therapeutic advances in hematology.

[3]  G. Marcucci,et al.  Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia , 2021, British journal of haematology.

[4]  B. Cho,et al.  Infections of Venetoclax-Based Chemotherapy in Acute Myeloid Leukemia: Rationale for Proper Antimicrobial Prophylaxis , 2021, Cancers.

[5]  Yonggoo Kim,et al.  Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients. , 2021, Transplantation and cellular therapy.

[6]  M. Konopleva,et al.  Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality , 2020, American journal of hematology.

[7]  A. Letai,et al.  Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study , 2020, American journal of hematology.

[8]  J. Welch,et al.  10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. , 2020, The Lancet. Haematology.

[9]  A. Tefferi,et al.  Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients , 2020, American journal of hematology.

[10]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[11]  G. Marcucci,et al.  Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia , 2020, American journal of hematology.

[12]  M. Pencina,et al.  Using Propensity Score Methods to Create Target Populations in Observational Clinical Research. , 2020, JAMA.

[13]  B. Cho,et al.  WT1 measurable residual disease assay in AML who underwent allogeneic hematopoietic stem cell transplantation; optimal time points, threshold, and candidates. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[15]  L. Tian,et al.  Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study , 2018, JAMA oncology.

[16]  H. Einsele,et al.  Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT , 2018, Journal of Hematology & Oncology.

[17]  C. Morgan.  Reducing bias using propensity score matching , 2018, Journal of Nuclear Cardiology.

[18]  A. Letai,et al.  Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.

[19]  D. Jupiter.  Propensity Score Matching: Retrospective Randomization? , 2017, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.

[20]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[21]  A. Letai,et al.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. , 2016, Cancer discovery.

[22]  Yongping Song,et al.  ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development , 2015, Journal of Hematology & Oncology.

[23]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[24]  James M. Bogenberger,et al.  Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies , 2015, Leukemia & lymphoma.

[25]  Peter E. Czabotar,et al.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy , 2013, Nature Reviews Molecular Cell Biology.

[26]  John M. Ashton,et al.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. , 2013, Cell stem cell.

[27]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Estey,et al.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[30]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[31]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[32]  Keith Wheatley,et al.  Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials , 2009, British journal of haematology.

[33]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.

[34]  D. Rubin.  Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation , 2001, Health Services and Outcomes Research Methodology.